Telephone
61.3.7067.6940
Address
Level 3 100 Cubitt Street Cremorne, Victoria (VIC) 3121
Description
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.1 - 0.36
Trade Value (12mth)
AU$4,776.00
1 week
13.64%
1 month
-7.41%
YTD
-60.94%
1 year
-64.29%
All time high
4.60055
EPS 3 yr Growth
183.600%
EBITDA Margin
N/A
Operating Cashflow
-$14m
Free Cash Flow Return
-70.20%
ROIC
-70.20%
Interest Coverage
N/A
Quick Ratio
7.50
Shares on Issue (Fully Dilluted)
146m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
31 May 23 |
Application for quotation of securities - CYP
×
Application for quotation of securities - CYP |
31 May 23 |
Cleansing Notice
×
Cleansing Notice |
31 January 23 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
31 January 20 |
Cynata Investor Presentation
×
Cynata Investor Presentation |
31 August 18 |
Cynata to Present at Rodman & Renshaw Investor Conference
×
Cynata to Present at Rodman & Renshaw Investor Conference |
31 August 11 |
Eco Quest Limited - Appendix 4E and Annual Report 30 June 2011 (ECQ-AU)
×
Eco Quest Limited - Appendix 4E and Annual Report 30 June 2011 (ECQ-AU) |
30 October 19 |
Cynata Corporate Presentation
×
Cynata Corporate Presentation |
30 November 10 |
MD Presentation to AGM (ECQ-AU)
×
MD Presentation to AGM (ECQ-AU) |
30 May 22 |
Cynata Adds New Site for MEND Clinical Trial
×
Cynata Adds New Site for MEND Clinical Trial |
30 May 19 |
Cynata's Cymerus Technology Featured in ISCT Presentations
×
Cynata's Cymerus Technology Featured in ISCT Presentations |
30 June 23 |
Cynata announces CEO succession and Board changes
×
Cynata announces CEO succession and Board changes |
30 June 23 |
Proposed issue of securities - CYP
×
Proposed issue of securities - CYP |
30 June 23 |
Notification regarding unquoted securities - CYP
×
Notification regarding unquoted securities - CYP |
30 July 10 |
Corporate Presentation to Broker (ECQ-AU)
×
Corporate Presentation to Broker (ECQ-AU) |
30 January 23 |
Cynata Receives IRB Approval for aGvHD Clinical Trial
×
Cynata Receives IRB Approval for aGvHD Clinical Trial |
30 August 22 |
Appointment of Ms Janine Rolfe to the Cynata Board
×
Appointment of Ms Janine Rolfe to the Cynata Board |
30 August 21 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
29 October 20 |
AusBiotech Conference Presentation
×
AusBiotech Conference Presentation |
29 October 13 |
Eco Quest Limited - CEO Presentation to AGM (ECQ-AU)
×
Eco Quest Limited - CEO Presentation to AGM (ECQ-AU) |
29 May 17 |
Cynata Investor Presentation May 2017
×
Cynata Investor Presentation May 2017 |
29 January 19 |
Clinical trial results to be presented at major symposium
×
Clinical trial results to be presented at major symposium |
29 December 21 |
FUJIFILM Cellular Dynamics Executes Manufacturing Agreement
×
FUJIFILM Cellular Dynamics Executes Manufacturing Agreement |
29 August 22 |
Preclinical study in coronary artery disease published
×
Preclinical study in coronary artery disease published |
29 April 22 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
28 October 09 |
Annual Report to shareholders (ECQ-AU)
×
Annual Report to shareholders (ECQ-AU) |
28 January 22 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.